ARS Pharmaceuticals Reports Submission Of sNDA For neffy 1 Mg For Treatment Of Type I Allergic Reactions, Including Anaphylaxis, In Children Who Weigh 15 To 30 Kg
Portfolio Pulse from Benzinga Newsdesk
ARS Pharmaceuticals has submitted a supplemental New Drug Application (sNDA) for neffy 1 mg, aimed at treating Type I allergic reactions, including anaphylaxis, in children weighing 15 to 30 kg.
September 09, 2024 | 8:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ARS Pharmaceuticals has submitted an sNDA for neffy 1 mg, targeting Type I allergic reactions in children. This regulatory step could expand the market for neffy, potentially boosting ARS Pharmaceuticals' revenue.
The submission of an sNDA for neffy 1 mg indicates a potential market expansion for ARS Pharmaceuticals, as it targets a new demographic (children 15-30 kg). If approved, this could lead to increased sales and revenue, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90